Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

LLY - Eli Lilly and Company Последние новости | Finranks

Home

/

LLY

E

Eli Lilly and Company (LLY)

NYQ – Цена в реальном времени. Валюта: USD

1220.33

+5.31 (0.44%)

Рынок открыт: Aug 12, 2026, 3:20 PM EDT

1218.00

+2.98 (0.25%)

Предыдущая сессия: Aug 11, 2026, 7:58 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)

I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)

I underestimated Eli Lilly and Company. LLY's Retatrutide showed promising efficacy in TRIUMPH-2/TRIUMPH-3 trials, and if approved by the FDA, I believe it could become the "gold standard" in the obesity market. Meanwhile, Jaypirca generated $192 million in sales for Eli Lilly in Q2, up 56.4% year-on-year, despite competitive pressure from AstraZeneca's Calquence and BeOne Medicines' Brukinsa.

Eli Lilly is suing pharmacies and peptide vendors over early sales of the next big weight-loss drug: retatrutide

Eli Lilly is suing pharmacies and peptide vendors over early sales of the next big weight-loss drug: retatrutide

Some Americans have turned to medical spas and pharmacies that sell peptides for health and wellness benefits for access to compounded versions of retatrutide.

Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs

Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs

Eli Lilly has filed six new lawsuits against U.S. entities that it alleges are selling a version of the company's investigational weight-loss drug on the black market.

Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

Eli Lilly on Wednesday said it ‌had filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide, escalating its campaign against unauthorized sellers before the medicine has won regulatory approval.

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors and shipping and logistics carriers—to help protect patients and fight this illicit activity.

Better Buy: Eli Lilly vs. Novo Nordisk

Better Buy: Eli Lilly vs. Novo Nordisk

Eli Lilly has a stronger GLP-1 portfolio and pipeline than Novo Nordisk. Eli Lilly also has a better lineup outside the diabetes and weight-loss areas.

2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now

2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now

SpaceX stock could underperform in the medium term as its valuation catches up with its fundamentals. Eli Lilly's fast-growing earnings justify its premium, and the stock is well-positioned to beat the market.

Видео

Wednesday's Final Takeaways: GOOGL AI Chief Leaves, GLP-1 Boosts LLY

Market Close: Stock Rally Fades, Job Growth Weakens, Strong Earnings Boost Eli Lilly 8-5-2026

Пресс-релизы

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors and shipping and logistics carriers—to help protect patients and fight this illicit activity.

05.08.2026

Positive

Inside Out: LLY and the Future of Weight Loss Drugs

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress

Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume. Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% to $8.38 on a non-GAAP basis.

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

INDIANAPOLIS, Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation, as determined by an FDA-approved test. Olomorasib is an investigational, potent and highly selective next-generation inhibitor of KRAS G12C.